MedTrace Logo

Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial

NCT03121573 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-04-20

No results posted yet for this study

Summary

The aim of this study was to investigate the effects of duloxetine on improvement of brain cortical activity in patients suffering from major depressive disorder using near infrared spectroscopy.

Conditions

Interventions

DRUG

Duloxetine

duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Study Design

Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-15
Primary Completion
2016-09-26
Completion
2017-01-17

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03121573 on ClinicalTrials.gov